Prostaglandin A inhibits replication of human immunodeficiency virus during acute infection Helmut Ankel,* t Ombretta Turriziani and Guido Antonelli
Institute of Virology, University 'La Sapienza', Viale di Porta Tiburtina 28, 00185 Rome, Italy An antiviral effect of prostaglandins (PGs) of the A series on the replication of human immunodeficiency virus (HIV) has been determined. In the T cell line C8166 under single growth cycle conditions, PGA~ reduced the number of infectious progeny 1000-fold in the absence of cytotoxicity. Thus, inhibition of HIV replication by PGA~ represents a true antiviral phenomenon. The number and size of virus-induced syncytia, and the amount of viral antigen were also drastically reduced. The effect was specific for PGAs because PGA2 was also inhibitory, whereas PGB~, PGE1 and PGE2 were inactive. Virus adsorption and penetration do not appear to be targets of antiviral action because PGA1 substantially reduced virus replication, even when added 5 h post-infection. PGA1 did not inhibit viral reverse transcriptase, as determined by in vitro assays, suggesting that its antiviral action is not the consequence of a direct inhibitory effect on this enzyme. PGA1 also inhibited the replication of HIV-1 in CEMx 174 cells, but with less potency. Previously, intravenous infusion of PGA1 into human volunteers has shown no significant deleterious side-effects and thus these observations suggest that PGAs might have potential as antiviral agents in humans.
Prostaglandins (PGs) are natural fatty acid derivatives with diverse physiological effects. Those of the A series and related compounds which share a common cyclopentenone structure show a remarkable inhibitory effect on the replication of several viruses, including Sendai (Santoro et al., 1989) , vesicular stomatitis (Santoro et al., 1983; Bader & Ankel, 1990) , influenza (Santoro et al., 1988) , encephalomyocarditis (Ankel et al., 1985) , vaccinia (Benavente et al., 1984) and herpes simplex viruses (Yamamoto et al., 1987) . What is remarkable is the fact that those viruses which can be inhibited include enveloped viruses with negative-sense ssRNA genomes and dsDNA genomes, as well as a non-enveloped, positive-sense ssRNA virus. Furthermore, these PGs interfere with virus replication when administered to infected cells, clearly differentiating them from antiviral agents such as interferons, which usually require cells to be treated before infection to be effective. An antiviral agent that is active after infection is clearly better for the treatment of virus disease. The fact that there are only a few substances with the potential to act against human immunodeficiency virus (HIV) prompted us to investigate the replication of HIV in the presence of PGs. This report shows that PGAs block replication of HIV during acute infection at concentrations that are not toxic to the host cell. Cultures of the CD4 ÷ human T cell line C8166 (Sodroski et al., 1984) were grown in RPMI 1640 containing 10% foetal bovine serum (FBS). To assay the antiviral activity of PGs, 7 x 106 cells were pelleted and infected with 1 ml of HIV-1pI, an isolate from an AIDS patient, at approximately 1 TCIDso per cell. After incubation at 37 °C for 1 h, cells were again pelleted and resuspended in RPMI 1640/10% FBS to 5 × 105 cells/ml, and put in the wells of 96-well culture plates (0.1 ml/well). Then, medium (0.1 ml)containing different concentrations of PGs (Sigma) was added in duplicate, the plates were incubated at 37 °C for 23 h. As seen under the microscope, the size and number of syncytia characteristic of HIV decreased substantially, resulting in almost complete disappearance of syncytia at a PGA1 concentration of 20 p.M (Fig. 1) . Infectious progeny were titrated after one cycle of replication (24 h) or as stated in the text, after being frozen and thawed three times to liberate intracellular virus (Dianzani et al., 1989) . As can be seen in Fig. 2 the titre of infectious virus progressively diminished, resulting in a 1000-fold inhibition at the highest non-toxic dose of PG. As infectivity decreased the amount of viral antigen, as determined by ELISA (Abbott Laboratories), also decreased (Fig. 3) . Sustained effects of PGA1 were seen when cells were infected at lower m.o.i.s and the virus titre was determined after multiple cycles (48 and 72 h; Table 1 ). The table also shows that the III-B laboratory strain ofHIV-1 (Popovic 0001-0320 © 1991 SGM al., 1984) was inhibited by PGA1 to a similar extent, showing that the sensitivity of the P-1 isolate was not unique.
The antiviral effect clearly is not the result of PGA1 cytotoxicity as determined from assays employing the conversion of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT; Sigma) to MTT formazan as a measure of cell integrity (Denizot & Lang, 1986) . In this assay uninfected C8166 cells were incubated for 24 h with PG at different concentrations. Then, 20 ~I of a 0-75 % MTT solution in PBS was added and incubation continued at 37 °C for 2 h. Cells were pelleted and any coloured crystals formed were dissolved in 0.04 M-HC1 in isopropanol. After centrifugation samples were read in an ELISA reader at 570 nm. Fifty percent cytotoxicity was determined from extrapolation of the values obtained and is defined as the PG concentration that yielded a 50% reduction in absorbance. As shown in Fig. 4 , whereas 50% inhibition of infectious virus yield occurred at an inhibitor concentration of approximately 2 ~tM, a 70-fold higher concentration was required to produce 50% cytotoxicity under conditions identical to those employed in the antiviral assays. Determination of thymidine incorporation into uninfected C8166 cells in the absence and the presence of up to 60 ~tM-PGA1 revealed no inhibition, and trypan blue exclusion tests corroborated these findings (data not shown).
As shown in Table 2 , the antiviral effect is not a general, non-specific phenomenon exerted by compounds that share amphiphilic characteristics, such as various PGs. In fact, at a pharmacological dosage of up to 40 ~tM, PGA2, but not PGB~, PGE1 or PGE2, had antiviral activity against HIV-1. Thus, the effect is not due to a general lipid-induced cell membrane alteration, but appears to be the consequence of a specific event with a requirement for a structural feature of PGAs.
To investigate whether the antiviral action affects early events in the virus replication cycle, we varied the time of addition of PGA1 to the infected cell cultures. As shown in Fig. 5 PGA1 could be added up to 5 h postinfection and still produce pronounced inhibition of virus propagation. However, antiviral action was not observed 6 h or later post-infection. Thus, events occurring after virus adsorption and penetration during the initial stages of virus replication must be the target of PGA1 action. However, up to 100 ~tM-PGA 1 did not show any inhibitory effect in an HIV-1 reverse transcriptase assay when added to reaction mixtures containing 10 ~tl of stock HIV-1p~ (106 TCIDs0/ml) and poly(A), oligo(dT), MgC12 and [32p]ATP, essentially as described by Willey et al. (1988) . Thus, at the present time, we cannot conclude whether virus inhibition is caused by an indirect effect on transcription inside the cells, or whether it involves a post-transcriptional event. It is interesting that in recent studies with vesicular stomatitis virus, a ssRNA virus with negative polarity, transcription of genomic RNA has been shown to be a major target of inhibition by PGA~ (Bader & Ankel, 1990) . However, in this case the product of viral polymerase is complementary RNA, whereas in the case of HIV it is complementary DNA. Also, the reverse transcriptase assay we used employs conditions different from those occurring inside the cell. An artificial template is used in We also investigated the effect of PGA1 on HIV-1p1 replication in CEM × 174 cells, another immortalized T cell line (Kong et al., 1988) . Virus assays in the absence and the presence of PGA1 were carried out as described for C8166 cells. Cells were infected with 0.1 TCID50 virus/cell and virus titres were determined after 48 and 72 h. As shown in Table 3 PGA1 also has an antiviral effect in this cell line, although it is much less pronounced. Using the MTT assay, no cytotoxicity was seen after incubation of control cells with 20 pM-PGA1 for 72 h, and 77~o of the cells survived at 30 ~tM. Thus the antiviral effect in CEM x 174 cells is not caused by cytotoxicity. Furthermore, from our data it appears that individual lines can differ in sensitivity to the antiviral action of PGAs, which might relate to differences in cellular binding, uptake and/or metabolism of these compounds by individual cell populations.
Are PGAs antiviral drugs which might be useful in the therapy of virus disease, specifically in the treatment of AIDS? In vivo studies with 16,16-dimethyl-PGA2, a long-acting PG analogue, have been carried out in BALB/c mice lethally infected with influenza virus (Santoro et al., 1988) . Daily intraperitoneal doses of l 0 ~tg per mouse over periods of up to 15 days were not toxic to control mice, as determined from the body weight of the animals. Furthermore, in infected mice the survival rate increased by an average of 40%. In addition, a significant decrease in the virus titres in the lungs of treated mice was noted 4 days after infection. On the other hand, the PG had no measurable effect on antibody response, delayed hypersensitivity or natural killer cell function in these animals. Thus, in these studies the survival of treated infected animals seems to be the direct consequence of the antiviral effect of the PG analogue. In studies on volunteers with hypertension, PGA1 has been infused at 0.25 ~tg/kg/min for 60 min or 1 to 2 ~tg/kg/min for 30 min with a beneficial effect on the patients' blood pressure (Lee et al., 1971 ; Westura et al., 1970) . No deleterious effects on kidney function nor other significant side-effects of the treatment were noted in these studies. Assuming that the PG was not rapidly metabolized to inactive derivatives, sequestered into body tissue or excreted during the infusion period, the circulating PGA1 concentration should have reached low antiviral levels, as shown in our studies with C8166 cells. However, it is evident that further evaluation of the safety and the antiviral efficacy of PGAs should be carried out in appropriate animal models.
